141 related articles for article (PubMed ID: 30580302)
1. Multiple 'doughnut' granulomas in a liver transplant patient with CMV reactivation.
Dejhansathit S; Miller AM; Suvannasankha A
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30580302
[No Abstract] [Full Text] [Related]
2. Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation.
Park GE; Ki HK; Ko JH
BMC Infect Dis; 2021 May; 21(1):414. PubMed ID: 33947335
[TBL] [Abstract][Full Text] [Related]
3. Fibrin ring granulomas in bone marrow in CMV infection.
Bihari C; Rastogi A; Nayak SL; Gupta E
Int J Lab Hematol; 2015 Aug; 37(4):e65-6. PubMed ID: 25369993
[No Abstract] [Full Text] [Related]
4. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
5. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma.
Nakagawa R; Onishi Y; Kawajiri A; Onodera K; Furukawa E; Sano S; Saito K; Ichikawa S; Fujiwara T; Fukuhara N; Harigae H
Ann Hematol; 2019 Aug; 98(8):1999-2001. PubMed ID: 30824957
[No Abstract] [Full Text] [Related]
6. Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient.
Kronig I; Elkrief L; Berney T; Van Delden C; Neofytos D
Transplantation; 2020 Aug; 104(8):e248-e249. PubMed ID: 32732860
[No Abstract] [Full Text] [Related]
7. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.
Reusser P
Expert Opin Investig Drugs; 2001 Sep; 10(9):1745-53. PubMed ID: 11772283
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy.
Pillet S; Pozzetto B; Roblin X
World J Gastroenterol; 2016 Feb; 22(6):2030-45. PubMed ID: 26877608
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus and kidney transplantation: a clinician's update.
De Keyzer K; Van Laecke S; Peeters P; Vanholder R
Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
[TBL] [Abstract][Full Text] [Related]
10. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.
Cvetković RS; Wellington K
Drugs; 2005; 65(6):859-78. PubMed ID: 15819597
[TBL] [Abstract][Full Text] [Related]
11. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
Mabilangan C; Preiksaitis JK; Cervera C;
Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
Kamar N; Mengelle C; Esposito L; Guitard J; Mehrenberger M; Lavayssière L; Ribes D; Cointault O; Durand D; Izopet J; Rostaing L
J Med Virol; 2008 Jun; 80(6):1012-7. PubMed ID: 18428146
[TBL] [Abstract][Full Text] [Related]
13. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
[TBL] [Abstract][Full Text] [Related]
15. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients.
Razonable RR
Infect Dis Clin North Am; 2013 Jun; 27(2):317-42. PubMed ID: 23714343
[TBL] [Abstract][Full Text] [Related]
16. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
17. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
[TBL] [Abstract][Full Text] [Related]
19. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
Freeman RB
Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
